Population Pharmacokinetics of Blinatumomab in Pediatric and Adult Patients with Hematological Malignancies.

ABSTRACT:

Background and objectives

Blinatumomab (BLINCYTO^®) is a novel bispecific T cell engager (BiTE^®) approved in the USA for the treatment of relapsed or refractory B cell precursor acute lymphoblastic leukemia (ALL) in children and adults, as well as minimal residual disease ALL in adults. This analysis characterized the population pharmacokinetics of intravenous blinatumomab in pediatric and adult patients.

Methods

A total of 2417 serum concentrations of blinatumomab from 674 patients, including adult (n = 628) and pediatric patients (n = 46), from eight clinical studies were analyzed. The impact of covariates on pharmacokinetic parameters were explored, and significant covariates were further evaluated using a simulation approach.

Results

Blinatumo

SUBMITTER: Clements JD 

PROVIDER: S-EPMC7109194 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature